Inicio › Linfoma no Hodgkin › Nebraska › Omaha
Ensayos clínicos de Linfoma no Hodgkin en Omaha, NE
14 estudios para Linfoma no Hodgkin buscan participantes en centros de Omaha y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutandoFase 2
- University of Nebraska Medical Center, Omaha
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
ReclutandoFase 1
- The University of Nebraska Medical Center, Omaha
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
ReclutandoFase 1/2
- Local Institution - 0124, Omaha
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
ReclutandoFase 2
- Nebraska Cancer Specialists, Omaha
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
ReclutandoFase 1/2
- University of Nebraska Medical Center, Omaha
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
ReclutandoFase 1
- University of Nebraska Medical Center, Omaha
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
ReclutandoFase 3
- University of Nebraska Medical Center (UNMC), Omaha
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
ReclutandoEstudio observacional
- University of Nebraska Medical Center, Omaha
Halt Aging in Survivors of Blood Cancers
Reclutando
- University of Nebraska Medical Center, Omaha
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
ReclutandoFase 1/2
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
ReclutandoFase 1/2
- Fred and Pamela Buffett Cancer Center, Omaha
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutandoFase 4
- University Of Nebraska Medical Center, Omaha
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutandoFase 4
- University Of Nebraska Medical Center, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Omaha
Ensayos de Linfoma no Hodgkin en otras ciudades
- Houston, TX31 estudios
- New York City, NY31 estudios
- Boston, MA26 estudios
- Nashville, TN21 estudios
- Philadelphia, PA20 estudios
- Baldwin Park, CA19 estudios
- Washington, DC18 estudios
- Milwaukee, WI18 estudios
- Atlanta, GA18 estudios
- Chicago, IL18 estudios
- Columbus, OH18 estudios
- Dallas, TX17 estudios
Otros estudios en Omaha
- Cáncer de próstata27 estudios
- Cáncer de pulmón de células no pequeñas24 estudios
- Cáncer de seno22 estudios
- Cáncer (todos los tipos)18 estudios
- Cáncer del colon y del recto18 estudios
- Mieloma múltiple16 estudios
- Cáncer de ovario14 estudios
- Cáncer de páncreas14 estudios
- Cáncer metastásico13 estudios
- Carcinoma de células escamosas de cabeza y cuello13 estudios
- Fallo cardíaco13 estudios
- Melanoma12 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.